Equities

Jiangsu Lianhuan Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Jiangsu Lianhuan Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)20.73
  • Today's Change-0.37 / -1.75%
  • Shares traded7.53m
  • 1 Year change+108.55%
  • Beta1.3111
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Jiangsu Lianhuan Pharmaceutical Co Ltd is a China-based company mainly engaged in pharmaceutical manufacturing and pharmaceutical distribution. The Company produces active pharmaceutical ingredients (APIs), tablets, injections and medical devices. The Company's main products include urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics and others, covering chemical APIs and injections, solid preparations and other drug dosage forms, including products such as Aprelet Tablets (Chuanliu), Ebastine Tablets (Sudi) and Felodipine Tablets (Lianhuanerding). The Company mainly conducts its businesses in the domestic and foreign markets.

  • Revenue in CNY (TTM)2.60bn
  • Net income in CNY-43.60m
  • Incorporated2000
  • Employees1.39k
  • Location
    Jiangsu Lianhuan Pharmaceutical Co LtdNo. 9 Health Road, YangzhouBiological Health Industrial ParkYANGZHOU 225127ChinaCHN
  • Phone+86 51 487813082
  • Fax+86 51 487815079
  • Websitehttp://www.lhpharma.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Jibeier Pharmaceutical Co Ltd957.76m241.67m5.75bn1.33k23.852.44--6.001.211.214.7911.820.37333.263.71721,747.909.378.9910.049.7887.9288.7225.1123.977.17--0.009232.974.1410.570.109514.2042.01--
Jiangsu Lianhuan Pharmaceutical Co. Ltd2.60bn-43.60m6.02bn1.39k--4.51--2.32-0.1527-0.15279.104.680.72793.284.161,872,001.00-0.80815.51-1.7410.7536.3651.36-1.117.340.79091.880.459230.61-0.627510.86-37.661.091.851.16
ChengDu Sheng Nuo Biotec Co Ltd638.35m120.09m6.15bn1.38k51.335.96--9.640.76150.76154.096.560.37140.9734.28462,238.306.986.0510.107.7555.3466.0018.8014.910.900814.110.386226.834.846.90-28.880.774151.66--
Hunan Warrant Pharmaceutical Co Ltd1.43bn213.03m6.17bn1.24k28.943.09--4.311.621.6210.8915.170.5541.407.991,154,661.007.619.478.7911.6159.1067.0313.7413.013.03--0.150314.11-1.3811.37-22.247.2157.23--
Kexing Biopharm Co Ltd1.52bn125.57m6.26bn947.0049.493.60--4.130.62880.62887.478.650.4734.202.901,601,171.003.82-0.18935.31-0.241363.1274.578.07-0.39561.3863.540.4489--11.753.39116.54-27.7411.90--
Data as of Feb 11 2026. Currency figures normalised to Jiangsu Lianhuan Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.12%Per cent of shares held by top holders
HolderShares% Held
Baoying Fund Management Co., Ltd.as of 30 Jun 2025142.10k0.05%
Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025125.50k0.04%
Everbright PGIM Fund Management Co. Ltd.as of 30 Jun 202532.70k0.01%
China Southern Asset Management Co., Ltd.as of 30 Jun 202517.70k0.01%
Western Leadbank Fund Management Co., Ltdas of 30 Jun 20257.40k0.00%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20255.80k0.00%
Orient Fund Management Co., Ltd.as of 30 Jun 20254.20k0.00%
Cinda Securities Co., Ltd. (Investment Management)as of 30 Jun 20253.30k0.00%
Wanjia Asset Management Co., Ltd.as of 30 Jun 20252.80k0.00%
Cinda Fund Management Co. Ltd.as of 30 Jun 20252.40k0.00%
More ▼
Data from 30 Jun 2025 - 30 Jun 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.